{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:13:42Z","timestamp":1789496022058,"version":"build-2803163510"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>DUAL I China, one of the DUAL trials, assessed efficacy\/safety of insulin degludec\/liraglutide (IDegLira) in Chinese adults with type 2 diabetes (T2D) not controlled by oral antidiabetic drugs (OADs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase 3a, treat\u2010to\u2010target multicenter trial randomized participants (glycated hemoglobin [HbA1c] 53.0\u201085.8\u2009mmol\/mol; previous metformin \u00b1 another OAD) 2:1:1 to IDegLira (n\u00a0=\u00a0361), degludec (n\u00a0=\u00a0179), or liraglutide (n\u00a0=\u00a0180). Primary endpoint was change in HbA1c after 26\u2009weeks. Secondary endpoints included: HbA1c\u2009&lt;\u200953.0\u2009mmol\/mol attainment, weight change, treatment\u2010emergent hypoglycemia, end\u2010of\u2010treatment insulin dose, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At 26\u2009weeks, HbA1c had decreased by a mean 18.12\u2009mmoL\/moL (IDegLira), 12.37\u2009mmoL\/moL (degludec) (estimated treatment difference [ETD] \u22126.50\u2009mmoL\/moL; 95% confidence interval [CI] \u22127.96, \u22125.04;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.0001), and 11.33\u2009mmoL\/moL (liraglutide) (ETD \u22126.87\u2009mmoL\/moL; 95% CI \u22128.33, \u22125.41;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), indicating noninferiority for IDegLira vs degludec and superiority vs liraglutide. HbA1c\u2009&lt;\u200953.0\u2009mmoL\/moL attainment was 77.0% (IDegLira), 46.4% (degludec), and 48.3% (liraglutide). Mean weight change with IDegLira (0.1\u2009kg) was superior to degludec (1.2\u2009kg) (ETD \u22121.08\u2009kg; 96% CI \u22121.55, \u22120.62;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Severe or confirmed hypoglycemic event rates were 0.24 (IDegLira) and 0.17 (degludec) episodes\/participant\u2010year (estimated rate ratio 1.46; 95% CI 0.71, 3.02;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u2009.3008, not significant). At the end of treatment, the IDegLira insulin dose was lower (24.5\u2009U\/d) vs degludec (30.3\u2009U\/d) (ETD \u22125.49\u2009U; 95% CI \u22127.77, \u22123.21;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). No unexpected safety issues occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IDegLira is efficacious and well tolerated in Chinese adults with T2D not controlled by OADs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1753-0407.13286","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T05:30:58Z","timestamp":1656394258000},"page":"401-413","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["<scp>DUAL<\/scp>\n                    I China: Improved glycemic control with\n                    <scp>IDegLira<\/scp>\n                    versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs"],"prefix":"10.1111","volume":"14","author":[{"given":"Weiqing","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Rui Jin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bue F. Ross","family":"Agner","sequence":"additional","affiliation":[{"name":"Bispebjerg Hospital Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Luo","sequence":"additional","affiliation":[{"name":"Novo Nordisk China Pharmaceuticals Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism Tianjin Medical University General Hospital Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongde","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Shanghai General Hospital Shanghai Jiao Tong University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism Shanghai Tenth People's Hospital of Tongji University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina Amelia","family":"Stachlewska","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism The First Hospital of Jilin University Jilin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyue","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism Affiliated Hospital of Jiangsu University Zhenjiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism The First Affiliated Hospital of Anhui Medical University Hefei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5754-7635","authenticated-orcid":false,"given":"Guang","family":"Ning","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Rui Jin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"IDF.IDF Diabetes Atlas 9th Edition 2019. Accessed December2 2019.https:\/\/www.diabetesatlas.org\/en\/resources\/"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3158","article-title":"Standards of medical care for type 2 diabetes in China 2019","volume":"2019","author":"Jia W","year":"2019","journal-title":"Diabetes Metab Res Rev."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12098"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3062"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2827-3"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2015.12.004"},{"key":"e_1_2_9_8_1","first-page":"26:353","article-title":"Hong Tianpei, Chen Zuozuo, Ji Qiuhe, Guo Lixin, Li Yanbing, Guo Xiaozuo, Li Hong, Shi Yongzuo, Li Qiang, Du Jianling, Yang Gangyi, Xiao Xinhua. Expert guidance on the clinical application of GLP\u20101 receptor agonists. Chinese journal of","author":"Ji Linong ZD","year":"2018","journal-title":"Diabetes."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70174-3"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0785"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0218-3"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13256"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13043"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12892"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1114"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30184-6"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13666"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315608646"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2014.0188"},{"key":"e_1_2_9_20_1","unstructured":"International Conference of Harmonisation.ICH harmonised tripartite guideline. Good clinical practice.1996."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2480"},{"key":"e_1_2_9_23_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER).Guidance for Industry Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. FDA;2008."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0824-8"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.054"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI33296"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7134.823"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573402114666180507152620"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615692"},{"key":"e_1_2_9_31_1","unstructured":"Novo Nordisk A\/S.TRESIBA\u00ae (insulin degludec injection) for subcutaneous use 2015. Accessed June 4 2021.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/tresiba\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_9_32_1","unstructured":"Novo Nordisk A\/S.VICTOZA\u00ae (liraglutide) for subcuteneous injection 2017. Accessed June 4 2021.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/victoza\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"}],"updated-by":[{"DOI":"10.1111\/1753-0407.13307","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000}}],"container-title":["Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1753-0407.13286","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1753-0407.13286","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1753-0407.13286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T15:56:59Z","timestamp":1700755019000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1753-0407.13286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/1753-0407.13286"],"URL":"https:\/\/doi.org\/10.1111\/1753-0407.13286","archive":["Portico"],"relation":{},"ISSN":["1753-0393","1753-0407"],"issn-type":[{"value":"1753-0393","type":"print"},{"value":"1753-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"2021-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}